MEK抑制剂相关的眼部不良事件综述
本文综述了MEK抑制剂治疗转移性BRAF突变黑色素瘤时出现的眼部不良事件,检索PubMed至2018年7月的文献。结果显示眼部不良事件发生率高达90%,包括视力下降、干眼、葡萄膜炎及MEK相关视网膜病变等,后者通常轻微自限。
要点
- MEK抑制剂眼部不良事件发生率可高达90%,包括无症状患者。
- MEK相关视网膜病变通常轻微、自限,持续用药或停药后可缓解。
- 眼部不良事件常与全身不良反应相关,需与肿瘤科医生沟通调整剂量。
核心结论
- MEK抑制剂可导致不同程度的视网膜、葡萄膜和眼附属器不良事件,引起视觉 disturbance 或不适。
- MEK相关视网膜病变通常轻微、自限,持续用药数周至数月或停药后可能消退并恢复视网膜正常视觉功能,但存在例外。
- 眼部不良事件常与可改变治疗剂量的其他全身不良反应相关,与肿瘤科医生的沟通至关重要。
研究设计与样本
- 通过PubMed数据库检索截至2018年7月的文献,使用「MEK inhibitors」结合「review」或「clinical trials」筛选,选取I-III期实验研究和综述。
主要发现
- 接受MEK抑制剂治疗的患者中,眼部不良事件发生率高达90%,包括无症状患者。
- 报告的眼部毒性从轻度到重度,包括视觉 disturbance、Snellen视力下降2行、干眼症状、眼附属器异常、视野缺损、全葡萄膜炎及视网膜毒性(如不同程度的MEK相关视网膜病变、血管损伤和视网膜静脉阻塞)。
关键数值与推荐
- 眼部不良事件发生率高达90%(接受MEK抑制剂治疗的患者,包括无症状者)。
- Snellen视力下降2行。
临床怎么用
- 需监测MEK抑制剂治疗患者的眼部不良事件,包括无症状者。
- MEK相关视网膜病变通常轻微自限,可继续用药观察或停药后恢复,但需注意例外情况。
- 眼部不良事件常伴随全身不良反应,应与肿瘤科医生沟通以调整治疗剂量。
局限性
- 文献检索截止至2018年7月,未涵盖此后新发表的研究。
- 仅选取I-III期实验研究和综述,可能遗漏其他类型研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance. This review aims to provide an update of the ocular adverse events (OAEs), especially retinal toxicity, associated with the use of MEK inhibitors. METHODS: We conducted a scientific literature search using the PubMed database up to July 2018 with the terms "MEK inhibitors" with a "review" filter and "MEK inhibitors" with a "clinical trials" filter. Phase I-III experimental studies and reviews were selected. Current principles and techniques for diagnosing and managing MEK inhibitor retinopathy and other OAEs are discussed. RESULTS: In patients treated with MEK inhibitors, including asymptomatic patients, OAEs occur with an incidence of up to 90%. Mild to severe ophthalmic toxicities are described, including visual disturbances, a 2-line decrease in Snellen visual acuity, dry eye symptoms, ocular adnexal abnormalities, visual field defects, panuveitis, and retinal toxicities, such as different degrees of MEK-associated retinopathy, vascular injury, and retinal vein occlusion. CONCLUSION: MEK inhibitors can lead to different degrees of retinal, uveal, and adnexal OAE, causing visual disturbances or discomfort. One of the most relevant OAE of MEK therapy is MEK inhibitor-associated retinopathy (MEKAR), which is usually mild, self-limited, and may subside after continuous use of the drug for weeks or months, or discontinuation, thereby restoring the normal visual function of the retina, with some exceptions. Ocular adverse events are often associated with other systemic adverse effects that can modify the dosage of treatment, so the communication with the oncologist is fundamental.
引用
- Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina. 2019. PMID: 30681641. doi:10.1097/IAE.0000000000002451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。